PRESS RELEASE: Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has

Read More

Health Economics model for OncoProg® commissioned

            Oxford Cancer Biomarkers Ltd partners with York Health Economics Consortium to demonstrate OncoProg ®

Read More

PRESS RELEASE: OncoProg receives CE mark

Oxford Cancer Biomarkers achieves CE mark for OncoProg ® digital pathology computational software product   OXFORD, UK – July 19th,

Read More

ColoProg becomes OncoProg

Oxford Cancer Biomarkers are pleased to announce the rebranding of our ColoProg ® product to OncoProg ®   OXFORD, UK

Read More

ToxNav ® validation data published

Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal

Read More

HAPB3 joins the ToxNav panel

The team at Oxford Cancer Biomarkers (OCB) are pleased to announce the expansion of our ToxNav® DPYD genomics panel with

Read More

Launching the 5FU Test Alliance

Today I am incredibly proud to be supporting the launch of the 5FU Test Alliance support group. They comprise a

Read More

OCB are presenting today with IBM at Pharmatec19 – London Room 7 at 11:20: Using AI Technology To Improve Outcomes For Cancer Patients

Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology

Read More